Novo Nordisk will explore how GLP-1 drugs could help patients struggling with addiction, its head of development Martin Holst ...

After Zepbound-maker Eli Lilly reduced the price of the weight-loss drug, competitor Novo Nordisk has cut the price of weight ...

Novo Nordisk said it will offer all doses of Wegovy for $499 a month to patients paying cash, a bid to reach consumers who ...

Key Takeaways Novo Nordisk is lowering the price of its weight-loss drug Wegovy to $499 per month for some patients paying ...

Some commercially insured patients stand to save $150 per month on Wegovy, a popular obesity medication. Patients on Medicare ...

Novo Nordisk is cutting the price of its weight-loss drug, Wegovy, and selling it through a direct-to-patient online pharmacy ...

The pharmacy, called NovoCare, will allow patients to pay $499 in cash per month for the blockbuster weight loss drug.

Makers of the popular obesity treatments Wegovy and Zepbound are cutting prices for people without insurance. Danish ...

Novo Nordisk said on Wednesday it would offer doses of its weight-loss drug Wegovy at a reduced cost of $499 per month for ...

Despite falling hard since last summer, shares of Novo Nordisk have more than doubled the market's overall performance. The ...

Novo Nordisk (NVO) plans to study how its GLP-1 drugs marketed as Wegovy and Ozempic for obesity and diabetes can help tackle ...

The Danish drugmaker has launched a new online pharmacy called NovoCare Pharmacy to cut out the middlemen it so frequently ...